N&N Asian subsidiary

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, with a primary focus on defeating diabetes and other serious chronic diseases such as obesity, rare blood disorders, and endocrine disorders. The company is best known for its leadership in the insulin market and its pioneering work with GLP-1 receptor agonists, including blockbuster products like Ozempic and Wegovy. Novo Nordisk operates extensive research, development, and manufacturing facilities worldwide, with a significant and growing presence across Asia through various regional subsidiaries. Their business model integrates drug discovery with large-scale manufacturing of biologics and delivery devices.